Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
US Stock MarketDetailed Quotes
DOYU DouYu
- 7.450
- -0.020-0.27%
Close Apr 1 16:00 ET
- 7.450
- 0.0000.00%
Post 16:05 ET
235.69MMarket Cap-5.60P/E (TTM)
7.700High7.380Low131.59KVolume7.480Open7.470Pre Close982.36KTurnover0.94%Turnover RatioLossP/E (Static)31.64MShares9.93052wk High0.41P/B104.29MFloat Cap1.36152wk Low--Dividend TTM14.00MShs Float37.837Historical High--Div YieldTTM4.28%Amplitude1.159Historical Low7.465Avg Price1Lot Size
DouYu Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -22.78%4.27B | -12.34%1.14B | -21.78%1.06B | -25.87%1.03B | -29.90%1.04B | -22.20%5.53B | -22.91%1.3B | -24.42%1.36B | -24.06%1.39B | -17.41%1.48B |
| Operating revenue | -22.78%4.27B | -12.34%1.14B | -21.78%1.06B | -25.87%1.03B | -29.90%1.04B | -22.20%5.53B | -22.91%1.3B | -24.42%1.36B | -24.06%1.39B | -17.41%1.48B |
| Cost of revenue | -18.56%3.95B | -8.85%1.07B | -14.10%1B | -21.23%947.82M | -28.77%930.68M | -20.79%4.85B | -21.76%1.17B | -24.58%1.17B | -21.05%1.2B | -15.81%1.31B |
| Gross profit | -52.66%323.83M | -44.72%69.79M | -68.39%60.82M | -55.42%84.22M | -38.23%109.01M | -30.91%684.03M | -32.14%126.25M | -23.41%192.42M | -38.88%188.9M | -27.61%176.47M |
| Operating expense | 6.47%888.05M | 8.85%253.33M | -22.97%155M | 3.75%203.78M | 35.44%275.95M | -29.85%834.1M | -3.86%232.72M | -23.30%201.23M | -42.16%196.41M | -40.94%203.74M |
| Selling and administrative expenses | -12.54%515.57M | -7.93%151.02M | -14.38%120.72M | -6.36%125.46M | -21.34%118.37M | -36.49%589.48M | -8.41%164.03M | -34.25%140.99M | -48.09%133.99M | -45.57%150.48M |
| -Selling and marketing expense | -11.54%311.14M | -5.54%79.35M | -11.93%79.26M | -11.58%76.96M | -16.67%75.57M | -45.03%351.73M | -32.21%84M | -44.49%90M | -48.02%87.05M | -51.34%90.69M |
| -General and administrative expense | -14.02%204.43M | -10.44%71.67M | -18.69%41.46M | 3.32%48.5M | -28.42%42.8M | -17.52%237.76M | 45.05%80.03M | -2.51%50.99M | -48.23%46.94M | -33.64%59.79M |
| Research and development costs | -34.40%181.68M | -42.19%34.15M | -41.96%43.24M | -29.43%50.14M | -25.12%54.15M | -27.71%276.94M | -26.68%59.07M | -11.69%74.51M | -30.25%71.04M | -37.83%72.31M |
| Other operating expenses | 690.47%190.81M | 608.56%68.15M | 37.19%-8.96M | 427.21%28.19M | 643.04%103.43M | 73.56%-32.31M | 154.71%9.62M | 60.85%-14.27M | 57.72%-8.62M | 60.16%-19.05M |
| Operating profit | -275.97%-564.22M | -72.38%-183.53M | -969.04%-94.18M | -1,491.23%-119.57M | -511.99%-166.94M | 24.54%-150.07M | -90.07%-106.47M | 20.74%-8.81M | 75.41%-7.51M | 73.04%-27.28M |
| Net non-operating interest income expense | -7.70%263.05M | -45.31%45.15M | -24.65%60.84M | 12.97%75.97M | 49.00%81.09M | 119.46%284.98M | 49.41%82.56M | 134.72%80.75M | 185.33%67.25M | 227.24%54.43M |
| Non-operating interest income | -7.70%263.05M | -45.31%45.15M | -24.65%60.84M | 12.97%75.97M | 49.00%81.09M | 119.46%284.98M | 49.41%82.56M | 134.72%80.75M | 185.33%67.25M | 227.24%54.43M |
| Other net income (expense) | 134.67%23.13M | 41.96%-20.86M | 3,043.91%44.17M | 98.51%-339K | 101.63%153K | 16.92%-66.71M | -103.10%-35.93M | 104.31%1.41M | 21.10%-22.79M | -717.75%-9.4M |
| Gain on sale of security | 880.99%1.24M | 547.15%546K | -1,850.00%-70K | -63.19%604K | 110.96%153K | --125.89K | ---122.11K | --4K | --1.64M | ---1.4M |
| Special income (charges) | --0 | --0 | ---- | ---- | --0 | ---13.97M | ---- | ---- | ---- | --0 |
| -Less:Impairment of capital assets | --0 | --0 | ---- | ---- | --0 | --13.97M | ---- | ---- | ---- | --0 |
| Other non- operating income (expenses) | 141.42%21.9M | 2.03%-21.4M | 3,057.89%44.24M | 96.14%-943K | ---- | 34.16%-52.87M | -23.47%-21.84M | 104.30%1.4M | 15.42%-24.43M | -596.26%-8M |
| Income before tax | -507.69%-278.04M | -166.08%-159.24M | -85.23%10.83M | -218.90%-43.93M | -582.69%-85.69M | 145.67%68.2M | -224.34%-59.85M | 889.47%73.34M | 203.01%36.95M | 120.71%17.75M |
| Income tax | 1,341.31%15.41M | 504.70%6.46M | 6.43M | 2.51M | 0 | -69.34%1.07M | -69.34%1.07M | 0 | 0 | 0 |
| Earnings from equity interest net of tax | 87.34%-4M | 251.25%1.98M | -132.75%-994K | 90.94%-2.73M | 30.13%-2.26M | -150.66%-31.61M | -102.05%-1.31M | 14.66%3.04M | -942.60%-30.1M | -182.37%-3.24M |
| Net income | -937.45%-297.44M | -163.12%-163.73M | -95.54%3.4M | -818.01%-49.17M | -705.86%-87.95M | 139.28%35.52M | -248.71%-62.23M | 1,249.74%76.38M | 117.67%6.85M | 116.71%14.52M |
| Net income continuous Operations | -937.45%-297.44M | -163.12%-163.73M | -95.54%3.4M | -818.01%-49.17M | -705.86%-87.95M | 139.28%35.52M | -248.71%-62.23M | 1,249.74%76.38M | 117.67%6.85M | 116.71%14.52M |
| Minority interest income | 0 | |||||||||
| Net income attributable to the parent company | -937.45%-297.44M | -163.12%-163.73M | -95.54%3.4M | -818.01%-49.17M | -705.86%-87.95M | 147.09%35.52M | -237.30%-62.23M | 2,670.75%76.38M | 122.15%6.85M | 116.71%14.52M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -937.45%-297.44M | -163.12%-163.73M | -95.54%3.4M | -818.01%-49.17M | -705.86%-87.95M | 147.09%35.52M | -237.30%-62.23M | 2,670.75%76.38M | 122.15%6.85M | 116.71%14.52M |
| Basic earnings per share | -969.37%-9.65 | -178.46%-5.43 | -95.40%0.11 | -852.38%-1.58 | -715.56%-2.77 | 147.03%1.11 | -237.32%-1.95 | 2,755.56%2.39 | 121.65%0.21 | 116.61%0.45 |
| Diluted earnings per share | -969.37%-9.65 | -178.46%-5.43 | -95.40%0.11 | -852.38%-1.58 | -715.56%-2.77 | 147.03%1.11 | -237.32%-1.95 | 2,755.56%2.39 | 121.65%0.21 | 116.61%0.45 |
| Dividend per share | ||||||||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
